223 related articles for article (PubMed ID: 30341505)
1. Outcomes of Stable Multiple Sclerosis Patients Staying on Initial Interferon Beta Therapy Versus Switching to Another Interferon Beta Therapy: A US Claims Database Study.
Cohan S; Smoot K; Kresa-Reahl K; Garland R; Yeh WS; Wu N; Watson C
Adv Ther; 2018 Nov; 35(11):1894-1904. PubMed ID: 30341505
[TBL] [Abstract][Full Text] [Related]
2. Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis.
Reder AT; Arndt N; Roman C; Geremakis C; Mendoza JP; Su R; Makin C; Avila RL; Vignos MC
Mult Scler Relat Disord; 2021 Jun; 51():102935. PubMed ID: 33882426
[TBL] [Abstract][Full Text] [Related]
3. Long-term efficacy and safety of intramuscular interferon beta-1a: Randomized postmarketing trial of two dosing regimens in Japanese patients with relapsing-remitting multiple sclerosis.
Saida T; Kira J; Ueno Y; Harada N; Hirakata T
Mult Scler Relat Disord; 2016 May; 7():102-8. PubMed ID: 27237769
[TBL] [Abstract][Full Text] [Related]
4. Effect of switching from intramuscular interferon β-1a to oral fingolimod on time to relapse in patients with relapsing-remitting multiple sclerosis enrolled in a 1-year extension of TRANSFORMS.
Meng X; Chin PS; Hashmonay R; Zahur Islam M; Cutter G
Contemp Clin Trials; 2015 Mar; 41():69-74. PubMed ID: 25545026
[TBL] [Abstract][Full Text] [Related]
5. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study.
Khatri B; Barkhof F; Comi G; Hartung HP; Kappos L; Montalban X; Pelletier J; Stites T; Wu S; Holdbrook F; Zhang-Auberson L; Francis G; Cohen JA;
Lancet Neurol; 2011 Jun; 10(6):520-9. PubMed ID: 21571593
[TBL] [Abstract][Full Text] [Related]
6. Postmarketing Safety Profile of Subcutaneous Interferon Beta-1a Given 3 Times Weekly: A Retrospective Administrative Claims Analysis.
Smith MY; Sabidó-Espin M; Trochanov A; Samuelson M; Guedes S; Corvino FA; Richy FF
J Manag Care Spec Pharm; 2015 Aug; 21(8):650-60. PubMed ID: 26233537
[TBL] [Abstract][Full Text] [Related]
7. Lateral switch to IFN beta-1a 44 mcg may be effective as escalation switch to fingolimod in selected persons with relapsing remitting multiple sclerosis: a real-world setting experience.
D'Amico E; Patti F; Zanghì A; Lo Fermo S; Chisari CG; Zappia M
Expert Rev Clin Pharmacol; 2018 May; 11(5):531-536. PubMed ID: 29521113
[TBL] [Abstract][Full Text] [Related]
8. Treatment Response Score to Glatiramer Acetate or Interferon Beta-1a.
Bovis F; Kalincik T; Lublin F; Cutter G; Malpas C; Horakova D; Havrdova EK; Trojano M; Prat A; Girard M; Duquette P; Onofrj M; Lugaresi A; Izquierdo G; Eichau S; Patti F; Terzi M; Grammond P; Bergamaschi R; Sola P; Ferraro D; Ozakbas S; Iuliano G; Boz C; Hupperts R; Grand'Maison F; Oreja-Guevara C; van Pesch V; Cartechini E; Petersen T; Altintas A; Soysal A; Ramo-Tello C; McCombe P; Turkoglu R; Butzkueven H; Wolinsky JS; Solaro C; Sormani MP
Neurology; 2021 Jan; 96(2):e214-e227. PubMed ID: 33024022
[TBL] [Abstract][Full Text] [Related]
9. Relapse rates in patients with multiple sclerosis switching from interferon to fingolimod or glatiramer acetate: a US claims database study.
Bergvall N; Makin C; Lahoz R; Agashivala N; Pradhan A; Capkun G; Petrilla AA; Karkare SU; McGuiness CB; Korn JR
PLoS One; 2014; 9(2):e88472. PubMed ID: 24516663
[TBL] [Abstract][Full Text] [Related]
10. The Assessment for Disinvestment of Intramuscular Interferon Beta for Relapsing-Remitting Multiple Sclerosis in Brazil.
de Lemos LLP; Guerra Júnior AA; Santos M; Magliano C; Diniz I; Souza K; Pereira RG; Alvares J; Godman B; Bennie M; Zimmermann IR; Dos Santos VCC; Pretramale CA; Acurcio FA
Pharmacoeconomics; 2018 Feb; 36(2):161-173. PubMed ID: 29139001
[TBL] [Abstract][Full Text] [Related]
11. Relapse outcomes, safety, and treatment patterns in patients diagnosed with relapsing-remitting multiple sclerosis and initiated on subcutaneous interferon β-1a or dimethyl fumarate: a real-world study.
Ernst FR; Barr P; Elmor R; Wong SL
Curr Med Res Opin; 2017 Dec; 33(12):2099-2106. PubMed ID: 28906152
[TBL] [Abstract][Full Text] [Related]
12. Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing-remitting multiple sclerosis at year 1.
Traboulsee A; Li DKB; Cascione M; Fang J; Dangond F; Miller A
BMC Neurol; 2018 Sep; 18(1):143. PubMed ID: 30217172
[TBL] [Abstract][Full Text] [Related]
13. Reasons for discontinuation of subcutaneous interferon β-1a three times a week among patients with multiple sclerosis: a real-world cohort study.
Sabidó-Espin M; Munschauer R
BMC Neurol; 2017 Mar; 17(1):57. PubMed ID: 28335743
[TBL] [Abstract][Full Text] [Related]
14. The STAR Study: a real-world, international, observational study of the safety and tolerability of, and adherence to, serum-free subcutaneous interferon β-1a in patients with relapsing multiple sclerosis.
Hupperts R; Ghazi-Visser L; Martins Silva A; Arvanitis M; Kuusisto H; Marhardt K; Vlaikidis N;
Clin Ther; 2014 Dec; 36(12):1946-1957. PubMed ID: 24811754
[TBL] [Abstract][Full Text] [Related]
15. Subcutaneous Interferon-β1a Does Not Increase the Risk of Stroke in Patients with Multiple Sclerosis: Analysis of Pooled Clinical Trials and Post-Marketing Surveillance.
Sabidó M; Venkatesh S; Hayward B; Aldridge J; Gillett A
Adv Ther; 2018 Nov; 35(11):2041-2053. PubMed ID: 30255416
[TBL] [Abstract][Full Text] [Related]
16. Glatiramer acetate and interferon beta-1a for intramuscular administration: a study of outcomes among multiple sclerosis intent-to-treat and persistent-use cohorts.
Castelli-Haley J; Oleen-Burkey MA; Lage MJ; Johnson K
J Med Econ; 2010; 13(3):464-71. PubMed ID: 20662760
[TBL] [Abstract][Full Text] [Related]
17. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
Schwid SR; Panitch HS
Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
[TBL] [Abstract][Full Text] [Related]
18. Effect of statins on clinical and molecular responses to intramuscular interferon beta-1a.
Rudick RA; Pace A; Rani MR; Hyde R; Panzara M; Appachi S; Shrock J; Maurer SL; Calabresi PA; Confavreux C; Galetta SL; Lublin FD; Radue EW; Ransohoff RM
Neurology; 2009 Jun; 72(23):1989-93. PubMed ID: 19506220
[TBL] [Abstract][Full Text] [Related]
19. Relapse rates in patients with multiple sclerosis treated with fingolimod: Subgroup analyses of pooled data from three phase 3 trials.
Derfuss T; Ontaneda D; Nicholas J; Meng X; Hawker K
Mult Scler Relat Disord; 2016 Jul; 8():124-30. PubMed ID: 27456887
[TBL] [Abstract][Full Text] [Related]
20. Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial.
Calkwood J; Cree B; Crayton H; Kantor D; Steingo B; Barbato L; Hashmonay R; Agashivala N; McCague K; Tenenbaum N; Edwards K
BMC Neurol; 2014 Nov; 14():220. PubMed ID: 25424122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]